Trader consensus heavily favors Anthropic remaining independent before 2027, with "No" at an implied 89.5% probability, driven by the company's aggressive expansion as an acquirer rather than a target—exemplified by its $400 million stock purchase of biotech startup Coefficient Bio yesterday to bolster Claude's healthcare and life sciences tools. Surging annualized revenue exceeding $19 billion, a $30 billion Series G round at $380 billion valuation in February, and preparations for a potential October 2026 IPO signal strong standalone viability amid enterprise adoption of Claude models. Ethical stances rejecting Pentagon contracts reinforce autonomy, though regulatory pressures or market shifts could introduce tail risks before resolution.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket · ОбновленоДа
НОВОЕ
НОВОЕ
31 дек. 2026 г.
Да
НОВОЕ
НОВОЕ
31 дек. 2026 г.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Trader consensus heavily favors Anthropic remaining independent before 2027, with "No" at an implied 89.5% probability, driven by the company's aggressive expansion as an acquirer rather than a target—exemplified by its $400 million stock purchase of biotech startup Coefficient Bio yesterday to bolster Claude's healthcare and life sciences tools. Surging annualized revenue exceeding $19 billion, a $30 billion Series G round at $380 billion valuation in February, and preparations for a potential October 2026 IPO signal strong standalone viability amid enterprise adoption of Claude models. Ethical stances rejecting Pentagon contracts reinforce autonomy, though regulatory pressures or market shifts could introduce tail risks before resolution.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Открытие рынка: Nov 12, 2025, 5:14 PM ET
Объем
$9,277Дата окончания
31 дек. 2026 г.Открытие рынка
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Trader consensus heavily favors Anthropic remaining independent before 2027, with "No" at an implied 89.5% probability, driven by the company's aggressive expansion as an acquirer rather than a target—exemplified by its $400 million stock purchase of biotech startup Coefficient Bio yesterday to bolster Claude's healthcare and life sciences tools. Surging annualized revenue exceeding $19 billion, a $30 billion Series G round at $380 billion valuation in February, and preparations for a potential October 2026 IPO signal strong standalone viability amid enterprise adoption of Claude models. Ethical stances rejecting Pentagon contracts reinforce autonomy, though regulatory pressures or market shifts could introduce tail risks before resolution.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Объем
$9,277Дата окончания
31 дек. 2026 г.Открытие рынка
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...Trader consensus heavily favors Anthropic remaining independent before 2027, with "No" at an implied 89.5% probability, driven by the company's aggressive expansion as an acquirer rather than a target—exemplified by its $400 million stock purchase of biotech startup Coefficient Bio yesterday to bolster Claude's healthcare and life sciences tools. Surging annualized revenue exceeding $19 billion, a $30 billion Series G round at $380 billion valuation in February, and preparations for a potential October 2026 IPO signal strong standalone viability amid enterprise adoption of Claude models. Ethical stances rejecting Pentagon contracts reinforce autonomy, though regulatory pressures or market shifts could introduce tail risks before resolution.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы